Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 4651–4700 of 75383
The Registrant, Albany International Corp. (the “Company”), has named Sean Valashinas its Vice President – Controller and Principal Accounting Officer and appointed him Principal Accounting Officer, both effective June 9, 2025.
On May 16, 2025, as part of a planned leadership succession, Suren Ajjarapu advised the Company that he was resigning from his position as the Company’s Chief Executive Officer and Chairman of the Board effective immediately.
the Company’s board of directors appointed Dr. Narasimhan Mani, age 50, and Dr. Shankar Hariharan, age 68, to serve as co-Chief Executive Officers of the Company effective as of May 20, 2025.
As part of the planned leadership transition, Prashant Patel also advised the Company that he was resigning from his position as the Company’s President and Chief Operating Officer, effective as of May 20, 2025.
The board of directors also appointed Dr. Mani to serve as a director on the Company’s board of directors to fill the vacancy created as a result of Mr. Ajjarapu’s resignation and appointed Dr. Hariharan to the position of Executive Chairman of the Company’s board of directors, each effective as of May 20, 2025.
the Board appointed H. Wyatt Flippen, current Board Member and Chief Executive Officer of the Company, as the new Chairman of the Board, effective immediately.
approved the removal of Bruce Brimacombe as Chairman of the Board, effective immediately.
On May 22, 2025, Anthony Johnson, a Director of the Company, provided written notice to the Company that he is resigning effective July 15, 2025.
the Board of Directors of the Company appointed Robert Strauss to serve as the Interim Chief Financial Officer of the Company, effective June 3, 2025
By mutual agreement on May 16, 2025, Mr. Rama will conclude his tenure at the Company effective June 2, 2025
On May 16, 2025, the Company appointed Michael Pruitt as interim Chief Executive Officer, effective immediately.
Effective May 16, 2025, the Board appointed Keith Johnson as a director of the Company.
Pursuant to the Separation Agreement, Mr. Wise resigned from all of his positions with the Company, including his positions as Chief Executive Officer, Chairman of the Board, and director.
Additionally, on May 16, 2025, Sangita Shah was appointed as Chairperson of the Board, effective immediately.
In connection with his appointment as interim Chief Executive Officer, Mr. Pruitt resigned from the Company’s Board.
The Company also announced the departure of Remy Gross from its Board of Directors effective May 22, 2025.
On May 22, 2025 , the Board of Directors of Serina Therapeutics, Inc. (the “Company”) appointed Dr. Stephen Brannan to the Company’s Board of Directors, effective May 22, 2025.
In addition, on May 20, 2025, the Company appointed Eduardo Serrano to serve as Legal Counsel and Senior Vice President, effective June 1, 2025.
On May 19, 2025, Richard Devlin, Senior Vice President and General Counsel of Unicoin Inc. (the “Company”), resigned from his position, effective immediately.
On May 21, 2025 Dutch Bros Inc. (the “Company”) determined that the service of Sumitro Ghosh as the President of Operations of the Company will conclude effective June 2, 2025, and the Company will thereafter eliminate the role of President of Operations.
Effective as of May 21, 2025, Amy Tu, Executive Vice President and Chief Legal & Compliance Officer, will step down from her role.
Christina Hennington, Executive Vice President and Chief Strategy and Growth Officer, will step down from her role, effective May 25, 2025.
Ira Robbins, the Company’s Chief Executive Officer, will assume the additional role of President of the Company and the Bank effective upon Mr. Iadanza’s retirement.
In connection with the previously announced retirement of Thomas A. Iadanza from his position as President of Valley National Bancorp (the “Company”) and Valley National Bank (the “Bank”) effective June 30, 2025, Ira Robbins, the Company’s Chief Executive Officer, will assume the additional role of President of the Company and the Bank effective upon Mr. Iadanza’s retirement.
the Board of Directors of UnitedHealth Group Incorporated (the “Company”) accepted Andrew Witty’s resignation as a director of the Company, effective immediately.
On May 21, 2025, the Board of Directors appointed Gregory C. McConnell Chairman, and Roxanne M. Page Vice Chairwoman, of the Boards of Directors of the Company and the Bank, effective July 5, 2025.
Chairman and Director Jack G. Hendon has tendered his retirement from the Board of Directors of the Company and the Bank, effective July 5, 2025.
On May 21, 2025, the Board of Directors appointed Gregory C. McConnell Chairman, and Roxanne M. Page Vice Chairwoman, of the Boards of Directors of the Company and the Bank, effective July 5, 2025.
appointed Rahul Patel as President and Chief Executive Officer of the Company, and as a member of the Board
appointed Rahul Patel as President and Chief Executive Officer of the Company, and as a member of the Board
Mr. Patel succeeds the Company's Chief Financial Officer, Ken Rizvi, who has served as the Company’s Interim Chief Executive Officer since February 2025.
Mr. Soriot was appointed to serve in the class of directors that will stand for re-election at the 2028 Annual Meeting of Stockholders.
Ms. Brown was appointed to serve in the class of directors that will stand for re-election at the 2026 Annual Meeting of Stockholders.
Effective May 21, 2025, the Board of Directors (the “Board”) of Flexsteel Industries, Inc. (the “Company”) appointed Terence P. Calloway to the Board.
Robert Bodor, who ceased to be the President and Chief Executive Officer and a director of the Company effective as of the Transition Date.
the Board of Directors (the “Board”) of the Company has appointed Suresh Krishna to serve as the Company’s President and Chief Executive Officer, effective May 20, 2025
The Board has also appointed Mr. Krishna to serve as a director of the Company
Robert Bodor, who ceased to be the President and Chief Executive Officer and a director of the Company effective as of the Transition Date.
On May 15, 2025, Dr. Yi Zeng, the director (the “Director”) of the Company, notified the board of directors of the Company (the “Board”) of his decision to resign his position on the Board of the Company and as a member of the audit committee of the Board , effective immediately.
On May 15, 2025, the Board of Directors (the “Board”) of United-Guardian, Inc. (the “Company”) appointed Donna Vigilante, the Company’s President to serve on the Board, effective immediately.
On May 15, 2025, Sam Klepfish resigned from his position as an independent member of the board of directors (“Board”) of Innovative Food Holdings, Inc. (the “Company”) and as a member of the Compensation Committee and Nominating and Corporate Governance Committee, effective immediately.
On May 20, 2025, the Company appointed Akhil Mahendra as interim Chief Financial Officer of the Company, effective May 30, 2025, to hold the position of interim Chief Financial Officer until his successor is appointed.
On May 19, 2025, Abhishek Khandelwal, Senior Vice President and Chief Financial Officer of IDEX Corporation (the “Company”), notified the Company of his decision to resign from his position, effective May 30, 2025, to pursue a new professional opportunity.
On May 21, 2025, MarketAxess Holdings Inc. (the “Company”) announced that it had appointed Dean Berry as its Group Chief Operating Officer and Chief Executive Officer, EMEA & APAC, effective as of his start date.
each of Alan Colowick, M.D., M.P.H., Patrick Machado, J.D., Beth Seidenberg, M.D., Bruce C. Cozadd, Dan Becker, M.D., Ph.D., Dawn Svoronos, Lynn Tetrault, J.D., Mina Kim and Henry O. Gosebruch ceased serving as a member of the board of directors of ACELYRIN and each committee thereof.
each of Alan Colowick, M.D., M.P.H., Patrick Machado, J.D., Beth Seidenberg, M.D., Bruce C. Cozadd, Dan Becker, M.D., Ph.D., Dawn Svoronos, Lynn Tetrault, J.D., Mina Kim and Henry O. Gosebruch ceased serving as a member of the board of directors of ACELYRIN and each committee thereof.
each of Alan Colowick, M.D., M.P.H., Patrick Machado, J.D., Beth Seidenberg, M.D., Bruce C. Cozadd, Dan Becker, M.D., Ph.D., Dawn Svoronos, Lynn Tetrault, J.D., Mina Kim and Henry O. Gosebruch ceased serving as a member of the board of directors of ACELYRIN and each committee thereof.
each of Alan Colowick, M.D., M.P.H., Patrick Machado, J.D., Beth Seidenberg, M.D., Bruce C. Cozadd, Dan Becker, M.D., Ph.D., Dawn Svoronos, Lynn Tetrault, J.D., Mina Kim and Henry O. Gosebruch ceased serving as a member of the board of directors of ACELYRIN and each committee thereof.
each of Alan Colowick, M.D., M.P.H., Patrick Machado, J.D., Beth Seidenberg, M.D., Bruce C. Cozadd, Dan Becker, M.D., Ph.D., Dawn Svoronos, Lynn Tetrault, J.D., Mina Kim and Henry O. Gosebruch ceased serving as a member of the board of directors of ACELYRIN and each committee thereof.
each of Alan Colowick, M.D., M.P.H., Patrick Machado, J.D., Beth Seidenberg, M.D., Bruce C. Cozadd, Dan Becker, M.D., Ph.D., Dawn Svoronos, Lynn Tetrault, J.D., Mina Kim and Henry O. Gosebruch ceased serving as a member of the board of directors of ACELYRIN and each committee thereof.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.